Clinical trials
Antiphospholipid Syndrome (APS) clinical trials
Below are recruiting antiphospholipid syndrome (aps) clinical trials, each written for real people, not researchers. We’re tracking 28 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07142239Recruiting
Blood markers in primary vs. secondary antiphospholipid syndrome
This study looks at three blood markers (MPV, PLR, and NLR) in people with antiphospholipid syndrome (APS) to see if they differ between primary APS (no other autoimmune disease) and secondary APS (with lupus or another autoimmune condition). It may help doctors better understand and manage APS.
Al Khārjah, Kharga OasisAges 18 years+ - NCT06373003Recruiting
Studying antiphospholipid syndrome without antibodies
This trial looks at people who have symptoms of antiphospholipid syndrome (APS) but test negative for the usual antibodies. It will compare these patients to those with positive antibody tests to better understand the condition and improve diagnosis and treatment.
Roma, RomeAges 18–65 - NCT06373926Recruiting
Blood test for Annexin A2 in antiphospholipid syndrome
This study tests how a blood sample can help doctors better understand Antiphospholipid Syndrome (APS) by measuring a protein called Annexin A2 on white blood cells. It may lead to easier diagnosis and monitoring of this condition.
AmiensAges 18 years+ - NCT06747312RecruitingPhase 2
Belimumab for antiphospholipid syndrome (APS)
This study tests if belimumab lowers harmful antibody levels in people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may help those who are already on a stable APS treatment plan.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07178925Recruiting
Long-term study of antiphospholipid syndrome
This trial follows patients with antiphospholipid syndrome over time to learn more about the condition. It may help researchers understand how the disease progresses and how to better manage it.
RouenAges 18–75 - NCT07372170Recruiting
Blood thinners for preventing another clot in low-risk APS
This study looks at how well blood thinners prevent blood clots from coming back in people with antiphospholipid syndrome (APS) who are considered low risk. It compares two types of medicines: direct oral anticoagulants (DOACs) and vitamin K antagonists.
Madrid, MadridAges 18 years+ - NCT00198068Recruiting
Study pregnancy outcomes in lupus and antiphospholipid syndrome
This study looks for factors that may predict how pregnancy turns out in people with lupus (SLE) and/or antiphospholipid syndrome (APS). It may help doctors better understand what to monitor in early pregnancy to support healthier outcomes.
Chicago, IllinoisAges 18–45 - NCT00616317Recruiting
Study for children with antiphospholipid syndrome and blood clots
This study is for children who have antiphospholipid syndrome (APS) and a history of blood vessel clots. Researchers want to learn more about APS in pediatric patients who have specific blood test signs and clot history.
Sacramento, CaliforniaAges 1 minute–18 years - NCT07584083RecruitingPhase 2
Anifrolumab for Primary Antiphospholipid Syndrome
This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.
Athens, GreeceAges 18–70 - NCT05583305Enrolling by invitation
Study brain artery narrowing causes in adults with antiphospholipid syndrome
This study looks at how often the brain’s arteries become narrowed in people with antiphospholipid syndrome (APS), and why it happens. It may help you and doctors better understand the cause and how to detect it early using a brain MRI scan.
Hong KongAges 18 years+ - NCT06371417RecruitingPhase 1
Testing RAY121 for several immune diseases (RAINBOW trial)
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
Orange, CaliforniaAges 18–85 - NCT06723106Enrolling by invitationPhase 1
Long-term safety study of RAY121 for immune conditions
This study is for people who already took RAY121 in a previous trial and did well. It tests whether continuing the treatment is safe and effective over a longer period. The goal is to manage chronic immune conditions.
Camperdown, New South WalesAges 18–85 - NCT00482794Recruiting
Study genetic risk factors for antiphospholipid antibody syndrome
This study looks at genetic (inherited) risk factors in people who have antiphospholipid antibodies and related symptoms. Your results may help researchers better predict who is at risk and improve care for antiphospholipid antibody syndrome.
Durham, North CarolinaAges Any age - NCT05995600RecruitingPhase 4
Clopidogrel vs warfarin to prevent a second APS stroke
This study compares two types of blood thinners — clopidogrel (an antiplatelet) and warfarin — to prevent another stroke in people with antiphospholipid syndrome (APS). It aims to find which medicine works better for people who have already had a stroke related to APS.
AnyangAges 19 years+ - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT05646394Recruiting
Registry for blood-clot prevention plans in arterial antiphospholipid syndrome
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
Buenos Aires, Buenos Aires F.D.Ages 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT07757789Recruiting
Platelet changes in antiphospholipid syndrome
This study looks at how platelet counts change over time in people with antiphospholipid syndrome (APS), a condition that can cause blood clots and pregnancy problems. It may help doctors better understand and manage low platelets in APS patients.
Al Khārjah, Kharga OasisAges 18 years+ - NCT05786235Recruiting
Pregnant people with or without antiphospholipid antibodies
This study is looking at pregnancy outcomes in people who are pregnant and either have antiphospholipid antibody syndrome (APS) or do not have APS but do have prior full-term pregnancies. It may help doctors understand risks and how to manage pregnancies in these groups.
MilanAges 18–45 - NCT05983952RecruitingPhase 2
Anti-CD38 antibody for APS with low platelets
This trial tests an anti-CD38 antibody in people with antiphospholipid syndrome (APS) who have very low platelet counts and haven't improved with steroids or other treatments. The goal is to see if it can safely raise platelet levels.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04262492Recruiting
Registry of adults with APS on blood thinners
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
NancyAges Any age - NCT05230017Recruiting
Study to follow people with antiphospholipid antibodies
This study looks at people who test positive for antiphospholipid antibodies on more than one blood test. It helps researchers better understand the condition and how to follow patients over time.
Beijing, Beijing MunicipalityAges Any age - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antiphospholipid syndrome (aps)?
- Yes. Clin2 currently lists 28 recruiting antiphospholipid syndrome (aps) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antiphospholipid syndrome (aps) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antiphospholipid syndrome (aps) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.